Literature DB >> 1001052

R34000, a dioxolane imidazole in the therapy for experimental coccidioidomycosis. Comparison with miconazole and econazole.

H B Levine.   

Abstract

Comparisons were made on the therapeutic influence of three imidazole drugs in experimental lethal coccidioidomycosis of mice. When administered by the intramuscular route, miconazole and a closely related structural analogue, econazole, were effective in preventing death, restricting fungal replication in the lungs, and minimizing the extent of extrapulmonary dissemination. Neither drug was as effective when administered by the oral route as by the intramuscular route. This contrasted sharply with results obtained using R34000, a dioxolane imidazole. It was very highly effective when administered by the oral route and less so by intramuscular injection. All orally treated mice survived a challenge lethal to more than 80 percent of control animals. Plasma or serum concentrations of orally administered R34000 in mice and in man exceeded the minimum inhibitory concentration for a virulent strain of Coccidioides immitis.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1001052     DOI: 10.1378/chest.70.6.755

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

Review 1.  Murine models of blastomycosis, coccidioidomycosis, and histoplasmosis.

Authors:  K N Sorensen; K V Clemons; D A Stevens
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

2.  Antifungal therapy, 1978.

Authors:  G L Baum
Journal:  Postgrad Med J       Date:  1979-09       Impact factor: 2.401

3.  Quantitation of imidazoles by agar-disk diffusion.

Authors:  J G Grendahl; J P Sung
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

Review 4.  Overview of medically important antifungal azole derivatives.

Authors:  R A Fromtling
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

Review 5.  Econazole: a review of its antifungal activity and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-09       Impact factor: 9.546

Review 6.  Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections.

Authors:  R C Heel; R N Brogden; G E Pakes; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-01       Impact factor: 9.546

7.  In vitro and in vivo studies of ambruticin (W7783): new class of antifungal antibiotics.

Authors:  S M Ringel
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

8.  Ketoconazole, an oral antifungal: laboratory and clinical assessment of imidazole drugs.

Authors:  D Borelli; J L Bran; J Fuentes; R Legendre; E Leiderman; H B Levine; A Restrepo; D A Stevens
Journal:  Postgrad Med J       Date:  1979-09       Impact factor: 2.401

Review 9.  Conazoles.

Authors:  Jan Heeres; Lieven Meerpoel; Paul Lewi
Journal:  Molecules       Date:  2010-06-09       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.